Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Mesa Laboratories Q2 2026 Results: Net Income $4.34M, Up 75.3% YoY

Mesa Laboratories reported Q2 2027 revenues of $31.6 million, a slight increase from $30.1 million in the prior year period. Net income for the quarter was $0.97 million ($0.16 per share), down from $1.63 million ($0.16 per share) in the same quarter last year, reflecting shifts in segment performance across sterilization, biopharmaceutical, and clinical genomics units.

Watch the Mesa Laboratories Inc earnings callFull call on the ALFA USA YouTube channel
Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue62.360.7
Gross profit39.937.3
Profit before tax6.02.0
Net income4.32.5
EPS (diluted, $ a share)$0.75$0.45

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+75.3%
Revenue, year on year+2.6%
Gross margin64.0%
Operating margin13.5%
Source

10-Q filed with the SEC, NASDAQ: MLAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mesa Laboratories Inc: key numbers

Share price
$134.09Close, Nov 16
Market cap
$754M
Shares outstanding
5.62MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Industrial Instruments For Measurement, Display, and ControlSIC 3823

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mesa Laboratories Inc

All →
4:36 PM ET 8-K
Financial Results

Mesa Laboratories Financial Results

Mesa Laboratories reported second quarter fiscal 2027 results with revenues increasing 2.6% to $62.3 million and net income rising 75.3% to $4.3 million. The company issued full-year fiscal 2027 guidance for the first time, forecasting revenues between $250 million and $255 million. Performance was driven by record revenues in the Sterilization and Disinfection Control division, partially offset by export-control delays in the Biopharmaceutical Development segment.

Term
Q2 2027

“Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product lines, and the Savings Plan we announced in October is under way. Today we are giving full-year guidance for the first time. We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter”

Dr. Siddhartha Kadia, President and CEO

“Second quarter revenues of $62,336 represented 2.6% organic (3.1% constant currency organic) growth, continuing positive organic growth in each quarter of FY27 to date. Growth was driven by SDC and CS, partially offset by BPD, which continued to be impacted by export-control processing delays, and CG. Adjusted EBITDA was 27.8% of revenues versus 23.5% in 2Q26. In the second quarter, we repaid $11,406 of debt and reduced our Total Net Leverage Ratio to 1.75”

John Sakys, Chief Financial Officer
8:01 AM ET 8-K
Business Update

Mesa Laboratories Business Update

Mesa Laboratories approved a restructuring program to reduce annualized operating costs by approximately $9.3 million, primarily by focusing its Clinical Genomics division on pharmacogenomics and oncology. The plan involves eliminating 40 positions (6% of the workforce) and exiting a facility in Hamburg, Germany, with an estimated $2.6 million to $3.4 million in pre-tax charges.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.